Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance

US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.

Vitiligo on the hands. Shutterstock 1621981522 — The US FDA continues to solicit patient input as it assembles a Voice of the Patient report for vitiligo, through methods old and new. • Source: Shutterstock

The US Food and Drug Administration’s first patient-focused drug development meeting of 2021 highlighted an undertreated condition, the skin pigmentation disorder vitiligo, that could be on the verge of seeing active new drug development.

With very few late-stage clinical trials of pharmaceutical interventions for vitiligo on record, the patient input from the meeting could help shape and nurture clinical trials in the field –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

22 May 2025

• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

22 May 2025

• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.